Abstract 24P
Background
A global survey reported that among 15 Asian countries, the Philippines has the highest breast cancer mortality rate and the lowest mortality-to-incidence ratio. Studies have described socioeconomic factors as one of the major causes for the lack of access to early detection and treatment.
Methods
In response to this gap in the delivery of services to promote early cancer detection and in line with the Breast Health Global Initiative’s call for low and middle income countries to adopt breast cancer screening to the local context, the University of the Philippines – Philippine General Hospital Cancer Institute (UP-PGH CI) established the Mobile Breast Cancer Diagnostic Clinic Program, a first in the country -two pink vans that are fully equipped to reach far flung areas and provide breast cancer screening strategies are sent out to deliver services.
Results
In the first 6 months of the program’s existence, the pink vans were able to visit 3 strategically identified areas in the country. These three tours served a total of 189 women who all underwent mammography. Of these women, 18 had their suspicious lesions biopsied. Two-thirds of which were found to be malignant. These patients were then advised to follow-up at our institute for further work-up and management.
Conclusions
As the Philippine health department continues to emphasize clinical and self-breast exam as part of its breast cancer control program, efforts like the UP-PGH “Pink Vans” may eventually help supplement the gap in the country’s breast cancer screening endeavors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session